Scientists succeed in human trials of HIV microbicide in Zimbabwe
By Yang Lina HARARE (Xinhua) 16 February 2009: Scientists have had the first successful human trials on a gel-PRO 2000 microbicide intended to prevent HIV infections in women in Zimbabwe, local media New Ziana reported on Monday.
http://news.xinhuanet.com/english/2009-02/17/content_10830339.htm
Zimbabwe's principal investigator with the University of Zimbabwe
working in collaboration with the University of California San
Francisco and Professor Mike Chirenje said research proved that PRO
2000 microbicide is 30 percent effective.
"Ideally, we would have wanted a 100 percent effectiveness. But this is
a starting point for us considering that there are several researches
on other gels done in the past and none of them proved such
effectiveness," Chirenje said during a presentation of trial
results.
The other microbicide Buffer Gel, which was tried concurrently with PRO
2000, however failed to protect women from contracting HIV from
positive partners.
Microbicides are substances intended to prevent the transmission of HIV
and other Sexually Transmitted Infections when applied inside a woman's
private parts. They come as gels, creams or a film. When applied to the
private parts, microbicide inhibits the virus from entering the human
body.
The microbicide research conducted between 2005 and 2008 involved 3,099
women drawn from South Africa, Zimbabwe, Zambia, Malawi and the United
States.
In Zimbabwe, the trials were conducted at Spilhaus in Harare and Seke
South Clinic in Chitungwiza and 484 women participated.
"A safe and effective microbicide could protect women and substantially
reduce new HIV infections here in Zimbabwe and globally. Although we
need additional evidence to determine with greater certainty whether
PRO 2000 is effective for preventing HIV, the results of this study
represent a significant step forward for HIV prevention research,"
Chirenje said.
He said as a way forward, a separate clinical study is currently
testing PRO 2000 on a larger scale and both results would be
compared.
"While these results are not conclusive, they provide a glimmer of hope
to millions of women at risk for HIV, especially young women in Africa.
These findings provide the first signal that a microbicide gel may be
able to protect women from HIV infection," said Dr Abdool Karim who led
the study in the four countries.
The study was necessitated by the fact that in Zimbabwe, women comprise
54 percent of all people living with HIV yet they have limited powers
to negotiate for safer intercourse.

